Vascular endothelial growth factor-165 (VEGF-165) is a homodimeric glycoprotein consisting of two domains: a heparin-binding domain and a receptor-binding domain. At least five different VEGF isoforms (VEGF-121, VEGF-145, VEGF-165, VEGF-189, VEGF-206) are known in humans, all of which are derived by alternative splicing of VEGF mRNA, but differ in their secretion and heparin-binding properties. Among VEGF isoforms, VEGF-165 is the most common and biologically active. It is an endothelial, cell-specific, and angiogenic growth factor that is a potent vascular permeability factor. VEGF-165 is released by many cell populations, including fibroblasts, monocytes, macrophages and lymphocytes. VEGF-165 induces vessel dilation by releasing nitric oxide and can have a chemotactic impact on other growth-promoting cell populations. VEGF-165 synthesis is stimulated most strongly by the lack of oxygen, an effect that is translated by hypoxia sensitive transcription factor, HIF1. Recombinant human VEGF-165 is a non-glycosylated homodimer, containing two 165 amino acids, with a total molecular weight of 38.2 kDa (2-5).
- Accession Number: P15692-4
- Synonyms: VEGF-A, VPF, glioma-derived endothelial cell mitogen
- Purity: ≥ 95% purity. Determined by HPLC, reducing and non-reducing SDS-PAGE, UV spectroscopy at 280nm.
- Bioactivity: ED50 is determined by dose-dependent proliferation of HUVECs The ED50 is typically less than 5ng/mL.
- Animal component-free and carrier-free
- Custom packaging available
For research or further manufacturing use only.
Also available in other sizes.